Why the study?
Does dsAAV-AM gene delivery reduce systolic blood pressure and prevent secondary cardiovascular and renal injuries in spontaneously hypertensive rats?
Population
Adult spontaneously hypertensive rats (SHR)
Comparison
Single dose of human adrenomedullin cDNA… vs Control groups
Design
Preclinical
Follow-up
up to 16 weeks
Authors
Loading...
Requires human trials before any clinical consideration; extends AAV gene therapy evidence in hypertensive rat models.
Does dsAAV-AM gene delivery reduce systolic blood pressure and prevent secondary cardiovascular and renal injuries in spontaneously hypertensive rats?
AAV-mediated adrenomedullin gene delivery provides long-term blood pressure reduction and protects against hypertensive cardiac and renal remodeling in a preclinical rat model.
Wei et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: